|
Amarantus BioSciences AMBS & Banyan Biomarkers Positive DataTraumatic Brain Injury Collaboration Amarantus BioSciences Inc., a biotechnology company developing newtreatments for brain-related disorders including traumatic braininjury (TBI), today announced the successful completion of acollaboration agreement initiated in November 2011 to evaluateMANF's potential as a disease-modifying agent for the treatment ofTBI. SUNNYVALE, CA, June 07, 2012 /24-7PressRelease/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS) , a biotechnology company developing new treatments forbrain-related disorders including traumatic brain injury (TBI)based on its proprietary anti-apoptotic therapeutic protein knownas MANF and Banyan Biomarkers, the leader in developing in vitrodiagnostic products to detect TBI, today announced the successfulcompletion of a collaboration agreement initiated in November 2011to evaluate MANF's potential as a disease-modifying agent for thetreatment of TBI. "Based on the results produced through this collaboration, weare excited about the potential of the MANF Program in generatingnew products to treat concussions and other forms of TBI,"said Gerald Commissiong, President & CEO of Amarantus."While this data is early on in development, we will belooking for innovative approaches to accelerate our TBI developmentprogram, while using Banyan's proprietary panel of markers as a keymetric in our companion drug - diagnostic strategy." In in-vitro cell culture experiments, MANF was reproducibly shownto confer neuroprotective properties in various cell death-relatedpathways. The data raise the possibility that modulating MANF inpatients immediately after suffering a TBI and in patients who havesuffered multiple concussions over an extended period, could be asuccessful therapeutic approach to promote recovery after TBI. "The data shows that MANF has a significant ability to reducecell death from a variety of insults that simulate Traumatic BrainInjury as we have modeled in multiple assays in our internallaboratories at Banyan," said Dr. Andreas Jeromin, PhD, SeniorDirector Research at Banyan, "These data give us confidence tomove to the next phase of testing to further validate thisapproach, as well as look at innovative product developmentstrategies to accelerate bringing a MANF-based treatment topatients for TBI." About Amarantus BioSciences, Inc. Amarantus BioSciences, Inc. is a development-stage biotechnologycompany founded in January 2008. The Company has a focus ondeveloping certain biologics surrounding the intellectual propertyand proprietary technologies it owns to treat Parkinson's disease,Traumatic Brain Injury and other human diseases. The Company ownsthe intellectual property rights to a therapeutic protein known asMesencephalic-Astrocyte-derived Neurotrophic Factor("MANF") and is developing MANF-based products astreatments for human disorders. The Company also is a FoundingMember of the Coalition for Concussion Treatment (#C4CT), amovement initiated in collaboration with Brewer SportsInternational seeking to raise awareness of new treatments indevelopment for concussions. For further information please visit. About Banyan Biomarkers Banyan Biomarkers is the leader in developing in vitro diagnosticproducts to address unmet clinical needs for the detection oftraumatic brain injury. The Company is focused on developing asimple point-of-care blood test that will be used by physicians todetect the presence and severity of brain trauma and improve themedical management of head injured patients. Banyan Biomarkers hasa licensing agreement with the University of Florida for exclusiveglobal use of technology related to this product. To learn moreabout Banyan Biomarkers, Inc., visit. Seraphim Strategies Lou Levenstein 727.489.9939 Forward Looking Statements This press release contains forward-looking statements within themeaning of the Private Securities Litigation Reform Act of 1995.Such statements include, but are not limited to, statements aboutthe possible benefits of MANF therapeutic applications and/oradvantages presented by Amarantus' PhenoGuard technology, as wellas statements about expectations, plans and prospects of thedevelopment of Amarantus' new product candidates. Theseforward-looking statements are subject to a number of risks,uncertainties and assumptions, including the risks that theanticipated benefits of the therapeutic drug candidates ordiscovery platforms, as well as the risks, uncertainties andassumptions relating to the development of Amarantus' new productcandidates, including those identified under "RiskFactors" in Amarantus' most recently filed Annual Report onForm 10-K and Quarterly Report on Form 10-Q and in other filingsAmarantus periodically makes with the SEC. Actual results maydiffer materially from those contemplated by these forward-lookingstatements Amarantus does not undertake to update any of theseforward-looking statements to reflect a change in its views orevents or circumstances that occur after the date of thispresentation. --- Press release service and press release distribution provided bywww.24-7pressrelease.com. I am an expert from custom-textileprinting.com, while we provides the quality product, such as China Personalized Pillow Cases , Custom Reusable Shopping Bag, Personalized Pillow Cases,and more.
Related Articles -
China Personalized Pillow Cases, Custom Reusable Shopping Bag,
|
